We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · November 24, 2022

Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial
J. Clin. Oncol 2022 Nov 04;[EPub Ahead of Print], J Pfisterer, F Joly, G Kristensen, J Rau, S Mahner, P Pautier, A El-Balat, JE Kurtz, U Canzler, J Sehouli, ML Heubner, AD Hartkopf, K Baumann, A Hasenburg, LC Hanker, A Belau, B Schmalfeldt, D Denschlag, TW Park-Simon, F Selle, C Jackisch, A Burges, HJ Lück, G Emons, W Meier, M Gropp-Meier, W Schröder, N de Gregorio, F Hilpert, P Harter

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading